Table 1.
Clinical Information.
Figure 1.
Signal intensity detected by RPPA.
A) Signal intensity (Y axis) for each case (X axis) for molecules of cyclin B1, IGFBP2, and caveolin 1. B) Alighted distribution of signals in normal and tumor tissues.
Table 2.
Levels of proteins in 101 lung cancer cases.*
Figure 2.
Protein levels detected by Western blot analysis.
Cyclin B1, caveolin 1, collagen type VI, ACC-pS79, CHK2, and IGFBP2 in normal and primary lung tumor tissues were analyzed by Western blot in at least four cases in which RPPA showed signal difference in normal and tumor tissues. The Western blot results were consistent with those yielded by RPPA.
Figure 3.
Examples of aberrant expression of 8 molecules in tumor tissue.
Increased expression of ACC-pS79, CHK2, IGFBP2, cyclin B1, STAT5, ATM, and Ku80, and decreased expression of caveolin 1 in tumor tissues were compared with normal tissues from the same cases shown withconsistent with findings yielded by RPPA and Western blot analyses. 40× Magnification.
Table 3.
Ability of using Nanjundan's training set to differentiate the whole data set of this study.
Figure 4.
Protein levels in tumor tissues and association with clinical parameters.
Protein levels in tumor tissues detected in RPPA assay were analyzed for associations with clinical parameters of patients. The molecule that was significantly different in tumors based on clinical parameters analyzed is shown on the top of each graph. The clinical parameters are shown at the bottom of each graph. The histology and differentiation diagnoses were based on pathological reports in clinical database. * indicates that the difference was significant when compared with other groups in the same graph (p<0.05).
Figure 5.
Association with Survival Outcomes.
Kaplan-Meier analysis on association of Stat5 levels and survival outcomes for Stage I–III (A) (n = 50 for each group), and Stage I only (B) patients (n = 33 for STAT5 high group, 34 for STAT5 low group).